Omura G, DiSaia P, Blessing J, Boronow R, Hreshchyshyn M, Park R
Cancer Treat Rep. 1977 Nov;61(8):1533-5.
In view of the need for drugs which have antitumor activity in alkylating agent-resistant ovarian cancer or which might be more potent than standard agents, a randomized trial of two nitrosoureas, CCNU and methyl-CCNU, has been conducted. Of 31 evaluable patients who received at least one dose of CCNU (100 mg/m2 orally every 6 weeks), there were only two patients who experienced even transient improvement; 18 of these patients had two or more doses over a trial period of greater than or equal to 12 weeks. Of 26 evaluable patients who received at least one dose of methyl-CCNU (150 mg/m2 orally every 6 weeks), there was one patient who experienced transient improvement; this group included 14 patients receiving at least two doses and whose trial lasted greater than or equal 12 weeks. All patients had been previously treated with mustard-type alkylating agents. None of the responses were clinically useful. Thus, women with ovarian adenocarcinoma who have a history of prior chemotherapy are not likely to benefit from treatment with these nitrosoureas.
鉴于需要在对烷化剂耐药的卵巢癌中具有抗肿瘤活性或可能比标准药物更有效的药物，已对两种亚硝基脲（洛莫司汀和甲环亚硝脲）进行了一项随机试验。在31例接受至少一剂洛莫司汀（每6周口服100mg/m²）的可评估患者中，只有2例患者有哪怕是短暂的病情改善；在大于或等于12周的试验期内，这些患者中有18例接受了两剂或更多剂。在26例接受至少一剂甲环亚硝脲（每6周口服150mg/m²）的可评估患者中，有1例患者有短暂的病情改善；该组包括14例接受至少两剂且试验持续大于或等于12周的患者。所有患者此前均接受过芥子气型烷化剂治疗。这些反应均无临床实用价值。因此，有先前化疗史的卵巢腺癌女性不太可能从这些亚硝基脲治疗中获益。
